STOCK TITAN
  1. Home
  2. News
  3. AGIO

Agios Pharmaceuticals, Inc. - AGIO STOCK NEWS

Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.

Agios Pharmaceuticals, Inc. (AGIO) is a biopharmaceutical company at the forefront of pioneering therapies for rare diseases, focusing on cellular metabolism and precision medicine. Based in Cambridge, Massachusetts, Agios is dedicated to discovering and developing breakthrough medications that target cancer, rare genetic metabolic disorders, and metabolic immuno-oncology. The company's core mission is to create transformative small-molecule medicines with a precision approach, enabling genetically or biomarker-defined patient populations to benefit from early proof-of-concept in clinical development.

Agios boasts a robust clinical pipeline, with significant advancements in its leading PK activator, mitapivat. Recent achievements include the Phase 3 ENERGIZE and ENERGIZE-T studies of mitapivat in thalassemia, demonstrating statistically significant results in reducing transfusion burdens in transfusion-dependent patients. The company is preparing for FDA submissions based on these promising outcomes, aiming to deliver the first oral treatment option for thalassemia patients.

Financially, Agios reported a net revenue of $8.2 million for the first quarter of 2024 from PYRUKYND® (mitapivat) sales, reflecting a 15% increase over the previous quarter. The company's strong cash position, with $714.3 million in cash, cash equivalents, and marketable securities as of March 31, 2024, ensures support for ongoing programs and potential pipeline expansion into 2026. Agios also anticipates a significant financial milestone with potential FDA approval of vorasidenib, expected to bring in $1.1 billion from upfront and milestone payments.

Agios' commitment to diversity and inclusion extends beyond its internal team to its clinical trials, aiming to build trust and support among diverse patient communities. The company’s strategic partnerships and collaborations further reinforce its mission to innovate and deliver life-changing therapies.

To stay updated on the latest developments and financial news about Agios Pharmaceuticals, visit their official website.

News

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

Rhea-AI Summary
Agios Pharmaceuticals, Inc. releases its 2024 ESG Report, focusing on red blood cell health, diversity, equity, and strong corporate governance. The report aligns with SASB standards and UN SDGs, emphasizing Agios' commitment to sustainability and social responsibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
none
-
News

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

Rhea-AI Summary
Agios Pharmaceuticals, Inc. will present at the Leerink Partners Global Biopharma Conference on March 12, 2024, showcasing their innovative therapies for rare diseases. The presentation will be available via live webcast and archived for two weeks on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
conferences
-
News

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

Rhea-AI Summary
Agios Pharmaceuticals, Inc. will present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The presentation will focus on the company's pioneering therapies for rare diseases in the field of cellular metabolism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.12%
Tags
conferences
News

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Rhea-AI Summary
Agios Pharmaceuticals, Inc. reported positive results from Phase 3 ENERGIZE Study of Mitapivat in Thalassemia and Phase 2 RISE UP Study in Sickle Cell Disease. Two more Phase 3 readouts expected in 2024. U.S. PYRUKYND® net revenue was $7.1 million in Q4 with cash reserves of $806.4 million as of Dec. 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
earnings
-
News

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

Rhea-AI Summary
Agios Pharmaceuticals, Inc. (AGIO) will host a conference call and live webcast to report its Q4 and year-end 2023 financial results and business highlights on February 15, 2024. The company specializes in cellular metabolism therapies for rare diseases and is a Nasdaq-listed leader in the field. The live webcast can be accessed on the company's website, with a replay available for at least two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conferences earnings
-
News

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Rhea-AI Summary
Agios Pharmaceuticals, a leader in cellular metabolism pioneering therapies for rare diseases, announced positive Phase 3 data for its lead PK activator, mitapivat, in non-transfusion-dependent thalassemia, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026. The company expects four additional Phase 3 readouts by the end of 2025 and has a strong cash position to support its ongoing programs and disciplined pipeline expansion at least into 2026. Agios has achieved significant milestones in 2023 and anticipates several more in 2024, positioning the company for potential launches of first- and best-in-class therapies in the near future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
none
News

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of hemoglobin response. Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
clinical trial
-
News

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
conferences
-
News

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) presented Phase 2 RISE UP study results of mitapivat for sickle cell disease at ASH 2023. Mitapivat demonstrated significant improvement in hemoglobin response and sickle cell pain crises. The Phase 3 dose has been selected, with a goal of reporting Phase 3 data in 2025 and potential U.S. approval in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
clinical trial
News

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Rhea-AI Summary
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced that 40% of low transfusion burden cohort achieved transfusion independence in the Phase 2a study of investigational pyruvate kinase (PK) activator AG-946 for anemia in adults with lower-risk myelodysplastic syndromes (LR-MDS). The safety profile was consistent with healthy volunteer study data. Agios plans to initiate Phase 2b study mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
clinical trial

FAQ

What is the current stock price of Agios Pharmaceuticals (AGIO)?

The current stock price of Agios Pharmaceuticals (AGIO) is $55.54 as of November 21, 2024.

What is the market cap of Agios Pharmaceuticals (AGIO)?

The market cap of Agios Pharmaceuticals (AGIO) is approximately 3.1B.

What does Agios Pharmaceuticals specialize in?

Agios Pharmaceuticals focuses on developing transformative small-molecule medicines for cancer, rare genetic metabolic disorders, and metabolic immuno-oncology.

What are some recent achievements of Agios Pharmaceuticals?

Agios has recently reported significant results from the Phase 3 ENERGIZE and ENERGIZE-T studies of mitapivat in thalassemia, showing a reduction in transfusion burdens for patients.

What is the financial status of Agios Pharmaceuticals?

As of March 31, 2024, Agios reported $8.2 million in net revenue from PYRUKYND® sales for the first quarter, with a strong cash position of $714.3 million.

What is mitapivat?

Mitapivat is a pyruvate kinase (PK) activator developed by Agios to treat hemolytic anemia in patients with pyruvate kinase deficiency and is under study for thalassemia and sickle cell disease.

What is the significance of the ENERGIZE-T study results?

The ENERGIZE-T study demonstrated that mitapivat significantly reduced transfusion burdens for patients with transfusion-dependent thalassemia, achieving all primary and key secondary endpoints.

How does Agios support diversity in clinical trials?

Agios prioritizes diversity by designing inclusive clinical trial protocols, building trust within diverse patient communities, and supporting trial awareness to ensure diverse participation.

What are some key upcoming milestones for Agios in 2024?

Agios plans to report topline data from the Phase 3 ENERGIZE-T study, complete enrollment in the RISE UP study for sickle cell disease, and file for regulatory approval of mitapivat in thalassemia by the end of 2024.

What strategic partnerships does Agios have?

Agios has strategic collaborations, including an agreement with Royalty Pharma for rights to its vorasidenib royalties, adding significant financial flexibility for the company's future endeavors.

What is Agios' approach to ESG?

Agios publishes an annual ESG report highlighting its commitments and actions in diversity, equity, inclusion, and strong corporate governance, aligning with global standards and goals.

How can I stay updated on Agios Pharmaceuticals?

For the latest news and updates, visit Agios Pharmaceuticals' official website at www.agios.com.

Stock AGIO logo
Agios Pharmaceuticals, Inc.

Nasdaq:AGIO

AGIO Rankings

#1656 Ranked by Market Cap
N/A Ranked by Dividends

AGIO Stock Data

3.10B
55.12M
1.51%
106.87%
7.61%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE